Engineered exosomes improve myocardial cell membrane integrity and heart function in dystrophic cardiomyopathy

Abstract

Background: Duchenne muscular dystrophy (DMD)-associated cardiomyopathy is a leading causes of premature death, yet treatment options remain limited. In this study, we developed the easily accessible engineered exosomes for treatment of DMD-associated cardiomyopathy and explored the underlying mechanisms in DmdΔ4 mice, a model harboring hot spot mutation in the dystrophin gene.

Methods: DmdΔ4 mice and their cardiomyopathy phenotype were confirmed by Sanger sequencing, pathological staining, flow cytometry, immunoblotting, single-cell sequencing and echocardiographic analysis. Engineered exosomes, exosomes- cardiac homing peptide (Exo-CHP), were synthesised and characterised by click chemistry and miRNA sequence, separately. The targeted ability and the therapeutic effects of Exo-CHP were studied in vitro and in vivo. Primary cardiomyocytes were used to study the underlying mechanism of Exo-CHP.

Results: DmdΔ4 mice showed an obvious cardiomyopathy-associated phenotype. Exo-CHP can target myocardium and mitigate pathological progression of cardiomyopathy in DmdΔ4 mice. The therapeutic effects of intravenously delivered Exo-CHP significantly reduced myocardial inflammation, fibrosis and improved the mice's cardiac function. The rescue effects were mediated through the regulation of gene expression at the transcriptomic level, prevention of dystrophin protein complex degradation, and inhibition of intracellular calcium influx and calpain protease activity. The miR-21 knockdown Exo-CHP can counteract the protective effects of Exo-CHP on the calcium content and membrane integrity of primary DmdΔ4-derived cardiomyocytes.

Conclusions: Our study demonstrated the feasibility, efficacy and the possible mechanism of mesenchymal stromal cell-derived engineered exosomes, positioning them as a potential cell-free intervention for DMD-associated cardiomyopathy.

Keywords

cardiomyopathy / Duchenne muscular dystrophy / engineered exosomes / mesenchymal stromal cells

References

[1] Kamdar F, Daniel JG. Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol. 2016; 67: 2533-2546.

[2] Schultz TI, Raucci FJ Jr, Salloum FN. Cardiovascular disease in Duchenne muscular dystrophy: overview and insight into novel therapeutic targets. JACC Basic Transl Sci. 2022; 7(6): 608-625.

[3] Landfeldt E, Thompson R, Sejersen T, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020; 35: 643-653.

[4] Kim S, Zhu Y, Romitti PA, et al. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Neuromuscul Disord. 2017; 27: 730-737.

[5] Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019; 15: 373-386.

[6] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367:eaau6977.

[7] Cecchin R, Troyer Z, Witwer K, et al. Extracellular vesicles: the next generation in gene therapy delivery. Mol Ther. 2023; 31: 1225-1230.

[8] Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023; 14: 66.

[9] Pan Y, Wu W, Jiang Y, et al. Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular disease: from mechanisms to therapy. Biomed Pharmacother. 2023; 163:114817.

[10] Bier A, Berenstein P, Kronfeld N, et al. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy. Biomaterials. 2018; 174: 67-78.

[11] Leng L, Dong X, Gao X, et al. Exosome-mediated improvement in membrane integrity and muscle function in dystrophic mice. Mol Ther. 2021; 29: 1459-1470.

[12] Tseliou E, Fouad J, Reich H, et al. Fibroblasts rendered antifibrotic, antiapoptotic, and angiogenic by priming with cardiosphere-derived extracellular membrane vesicles. J Am Coll Cardiol. 2015; 66: 599-511.

[13] Chen Z, Xiong M, Tian J, et al. Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review. J Nanobiotechnol. 2024; 22(1): 18.

[14] Li L, Wang F, Zhu D, et al. Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundam Res. 2024; 5(2): 851-867.

[15] Kanki S, Jaalouk DE, Lee S, et al. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol. 2011; 50: 841-848.

[16] Won YW, McGinn AN, Lee M, et al. Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Mol Pharm. 2013; 10: 378-385.

[17] Vandergriff A, Huang K, Shen D, et al. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide. Theranostics. 2018; 8: 1869-1878.

[18] Liu H, Yan W, Ma C, et al. Early detection of cardiac fibrosis in diabetic mice by targeting myocardiopathy and matrix metalloproteinase 2. Acta Biomater. 2024; 176: 367-378.

[19] Wang H, Zou W, Tian F, et al. Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice. Nat Commun. 2024; 15: 6058.

[20] Rogers RG, Fournier M, Sanchez LL, et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice. JCI Insight. 2019; 4:e130202.

[21] Aminzadeh MA, Rogers RG, Fournier M, et al. Exosomes-mediated benefits of cell therapy in mouse and human models of Duchenne muscular dystrophy. Stem Cell Rep. 2018; 10: 942-955.

[22] Siemionow M, Malik M, Langa P, et al. Cardiac protection after systemic transplant of dystrophin expressing chimeric (DEC) cells to the mdx mouse model of Duchenne muscular dystrophy. Stem Cell Rev Rep. 2019; 15: 827-841.

[23] Su X, Shen Y, Jin Y, et al. Identification of critical molecular pathways involved in exosome-mediated improvement of cardiac function in a mouse model of muscular dystrophy. Acta Pharmacol Sin. 2021; 42: 529-535.

[24] Oliveira-Santos A, Dagda M, Burkin DJ. Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy. Hum Mol Genet. 2022; 31: 2358-2369.

[25] Morroni J, Schirone L, Valenti V, et al. Inhibition of PKCθ improves dystrophic heart phenotype and function in a novel model of DMD cardiomyopathy. Int J Mol Sci. 2022; 23: 2256.

[26] Tang R, Liu G, Wang C, et al. Encapsulated bifunctional nanosheets targeting the immune-PI3K/Akt axis for osteoporosis therapy. Adv Sci. 2025; 12(47):e11327.

[27] Wu G, Su T, Zhou P, et al. Engineering M2 macrophage-derived exosomes modulate activated T cell cuproptosis to promote immune tolerance in rheumatoid arthritis. Biomaterials. 2025; 315:122943.

[28] Putten M, Hulsker M, Young C, et al. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J. 2013; 27: 2484-2495.

[29] Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004; 5: 872-876.

[30] Barana A, Matamoros M, Pablo D, et al. Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current. Circ Arrhythm Electrophysiol. 2014; 7(5): 861-868.

[31] Shah MNA, Yokota T. Cardiac therapies for Duchenne muscular dystrophy. Ther Adv Neurol Disord. 2023; 16:17562864231182934.

[32] Canonico F, Chirivi M, Maiullari F, et al. Focus on the road to modelling cardiomyopathy in muscular dystrophy. Cardiovasc Res. 2022; 118: 1872-1884.

[33] Swiderski K, Lynch GS. Murine models of Duchenne muscular dystrophy: is there a best model? Am J Physiol Cell Physiol. 2021; 321: C409-C412.

[34] Young CS, Mokhonoba E, Quinonez M, et al. Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR/Cas9 gene editing therapy. J Neuromuscul Dis. 2017; 4: 139-145.

[35] Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy. Hum Mutat. 2015; 36: 395-402.

[36] Egorova TV, Zotova ED, Reshetov DA, et al. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. Dis Model Mech. 2019; 12:dmm037655.

[37] Li J, Wang K, Zhang Y, et al. Therapeutic exon skipping through a CRISPR-guided cytidine deaminase rescues dystrophic cardiomyopathy in vivo. Circulation. 2021; 144: 1760-1776.

[38] Coley WD, Bogdanik L, Vila MC, et al. Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet. 2016; 25: 130-145.

[39] Ran N, Gao X, Dong X, et al. Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice. Biomaterials. 2020; 236:119826.

Rights & permissions

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.